Drug Profile
Research programme: zwitterionic polysaccharides - Wellstat ImmunoTherapeutics
Alternative Names: ZPS - Wellstat ImmunoTherapeuticsLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Wellstat ImmunoTherapeutics
- Class Anti-inflammatories; Polysaccharides
- Mechanism of Action Immunomodulators; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Aug 2020 No recent reports of development identified for research development in Inflammation in USA
- 18 Jul 2016 Early research in Autoimmune disorders in USA (unspecified route)